XOMA's revenue grew substantially while the company reduced R&D spending and experienced a notable decline in cash reserves.
The substantial revenue expansion alongside reduced R&D expenses suggests XOMA is benefiting from its royalty portfolio strategy, though the declining cash position and increased current liabilities warrant monitoring. The extensive changes in subsidiary and agreement definitions indicate significant business development activity, potentially explaining the revenue growth through new royalty acquisitions or partnerships.
XOMA's financial profile shows substantial revenue growth accompanied by operational discipline through reduced R&D spending and modest SG&A cost reductions. However, the company's liquidity position weakened with cash declining 18.4% to $82.9M while current liabilities increased 42.9% to $34.8M, suggesting either increased investment activity or operational cash consumption. Despite these near-term pressures, total assets grew 23.2% to $272.7M, indicating the company is expanding its asset base, likely through royalty acquisitions consistent with its business model transformation.
Strong top-line growth of 83.1% — accelerating demand or successful expansion into new markets.
Current liabilities surged 42.9% — significant near-term obligations; verify ability to meet short-term debt.
R&D spending cut 40.5% — could signal cost discipline or concerning reduction in innovation investment.
Asset base grew 23.2% — expansion through organic growth, acquisitions, or capital deployment.
Liabilities increased 21.1% — monitor debt-to-equity ratio and interest coverage.
Cash decreased 18.4% — monitor burn rate and upcoming capital needs.
SG&A reduced 11.1% — improved cost efficiency or headcount reduction improving operating margins.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →